The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
AstraZeneca jumps as tozorakimab hits primary goals in two phase III COPD trials, cuts exacerbations and shows promise in a ...
AstraZeneca PLC (NASDAQ:AZN) has delivered a solid trailing 12 months, with shares up 31.43% over the past year. Year-to-date ...
AstraZeneca jumps 4% after COPD drug wins Phase 3 trials. Tozorakimab success seen as rare win in tough COPD drug race.
Investor's Business Daily on MSN
AstraZeneca zips higher on its double win in COPD treatment
AstraZeneca stock jumped Friday after the U.K.-based drugmaker said its COPD drug succeeded in two final-phase studies.
AstraZeneca plans a $15B China investment amid cardio-metabolic and oncology growth. Read the latest analysis on AZN stock ...
Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early ...
If you are wondering whether AstraZeneca's current share price aligns with the value you are getting as an investor, this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results